A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. We are advancing the development of our lead product candidate, AXN-2510/IMM2510, a bispecific antibody targeting both programmed death-ligand 1, or PD-L1, and vascular endothelial growth factor, or VEGF, in solid tumor cancers, and we seek to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. In August 2024, our wholly owned subsidiary, Axion Bio, Inc. (formerly SynBioTx, Inc.), or Axion Bio, in-licensed certain bispecific antibodies, including AXN-2510 (formerly SYN-2510)/IMM2510 and AXN-27M (formerly SYN-27M)/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4, from ImmuneOnco Biopharmaceuticals (Shanghai) Inc., or ImmuneOnco.
| Metric | TTM | FY2021 | FY2020 |
|---|---|---|---|
| Revenue | 0 | 0 | - |
| Net Income | -75M | -157M | -38M |
| EPS | $-11.35 | $-29.60 | $-47.20 |
| Free Cash Flow | 0 | -180M | -80M |
| ROIC | -55.7% | -28.2% | -8.3% |
| Gross Margin | - | - | - |
| Debt/Equity | 0.00 | 0.10 | -0.67 |
| Dividends/Share | $0.00 | - | - |
| Operating Income | -81M | -156M | -34M |
| Operating Margin | 0.0% | - | - |
| ROE | -62.3% | -60.8% | - |
| Shares Outstanding | 7M | 5M | 6M |
| Metric | 2020 | ||
|---|---|---|---|
| Income Statement | |||
| Revenue | N/A | 0 | 0 |
| Gross Margin | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A |
| EBIT | -34M | -156M | -81M |
| Op. Margin | N/A | N/A | 0.0% |
| Net Income | -38M | -157M | -75M |
| Net Margin | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 |
| Returns on Capital | |||
| ROIC | -8.3% | -28.2% | -55.7% |
| ROE | N/A | -60.8% | -62.3% |
| ROA | -11.8% | -33.8% | -35.5% |
| Cash Flow | |||
| Op. Cash Flow | -30M | -122M | -40M |
| Free Cash Flow | -80M | -180M | 0 |
| Owner Earnings | -32M | -151M | -69M |
| CapEx | 51M | 58M | 0 |
| Maint. CapEx | 256K | 2.8M | 2.8M |
| Growth CapEx | 51M | 55M | 0 |
| D&A | 256K | 2.8M | 2.8M |
| CapEx/OCF | N/A | N/A | 0.0% |
| Capital Allocation | |||
| Dividends Paid | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.7M | 26M | 26M |
| Debt Repayment | 0 | 0 | 0 |
| Balance Sheet | |||
| Net Debt | N/A | N/A | -5.8M |
| Cash & Equiv. | N/A | N/A | 5.8M |
| Long-Term Debt | N/A | N/A | N/A |
| Debt/Equity | -0.67 | 0.10 | 0.00 |
| Interest Coverage | N/A | N/A | N/A |
| Equity | -40M | 555M | 120M |
| Total Assets | 319M | 610M | 212M |
| Total Liabilities | 27M | 55M | 91M |
| Intangibles | 5.7M | 5.7M | 5.7M |
| Retained Earnings | -45M | -202M | -202M |
| Working Capital | 233M | 423M | 423M |
| Current Assets | 246M | 464M | 464M |
| Current Liabilities | 13M | 41M | 41M |
| Per Share Data | |||
| EPS | -47.20 | -29.60 | -11.35 |
| Owner EPS | -4.89 | -28.52 | -10.18 |
| Book Value | -6.13 | 104.81 | 17.76 |
| Cash Flow/Share | -4.59 | -23.06 | -10.66 |
| Dividends/Share | N/A | N/A | 0.00 |
| Shares Out. | 6.5M | 5.3M | 6.8M |
| Valuation | |||
| P/E Ratio | N/A | N/A | -0.7 |
| P/FCF | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A |
| Price/Book | N/A | 3.2 | 0.5 |
| Price/Sales | N/A | N/A | N/A |
| FCF Yield | N/A | -10.1% | N/A |
| Market Cap | N/A | 1.8B | 57M |
| Avg. Price | N/A | 383.60 | 8.44 |
| Year-End Price | N/A | 335.20 | 8.44 |
Instil Bio, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Instil Bio, Inc. (TIL) has a 5-year average return on invested capital (ROIC) of -18.3%. This is below average and may indicate limited pricing power.
Instil Bio, Inc. (TIL) has a market capitalization of $57M. It is classified as a small-cap stock.
Instil Bio, Inc. (TIL) does not currently pay a regular dividend.
Instil Bio, Inc. (TIL) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Instil Bio, Inc. (TIL) generated $-180 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Instil Bio, Inc. (TIL) has a debt-to-equity ratio of 0.10. This indicates a conservatively financed balance sheet.
Instil Bio, Inc. (TIL) reported earnings per share (EPS) of $-29.60 in its most recent fiscal year.
Instil Bio, Inc. (TIL) has a return on equity (ROE) of -60.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 2 years of financial data for Instil Bio, Inc. (TIL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Instil Bio, Inc. (TIL) has a book value per share of $104.81, based on its most recent annual SEC filing.